Iron deficiency up-regulates iron absorption from ferrous sulphate but not ferric pyrophosphate and consequently food fortification with ferrous sulphate has relatively greater efficacy in iron-deficient individuals

Michael B. Zimmermann1,2*, Ralf Biebinger1,3, Ines Eglı1, Christophe Zeder1 and Richard F. Hurrell1
1Laboratory for Human Nutrition, Institute of Food Science and Nutrition, Swiss Federal Institute of Technology (ETH) Zurich, Schmelzbergstrasse 7, LFV E19, CH-8092 Zurich, Switzerland
2Human Nutrition Division, Wageningen University, Wageningen, The Netherlands
3DSM Nutritional Products, Kaiseraugst, Switzerland
(Received 16 October 2010 – Revised 19 October 2010 – Accepted 27 October 2010 – First published online 17 December 2010)

Abstract
Fe absorption from water-soluble forms of Fe is inversely proportional to Fe status in humans. Whether this is true for poorly soluble Fe compounds is uncertain. Our objectives were therefore (1) to compare the up-regulation of Fe absorption at low Fe status from ferrous sulphate (FS) and ferric pyrophosphate (FPP) and (2) to compare the efficacy of FS with FPP in a fortification trial to increase body Fe stores in Fe-deficient children and Fe-sufficient children. Using stable isotopes in test meals in young women (n 49) selected for low and high Fe status, we compared the absorption of FPP with FS. We analysed data from previous efficacy trials in children (n 258) to determine whether Fe status at baseline predicted response to FS v. FPP as salt fortificants. Plasma ferritin was a strong negative predictor of Fe bioavailability from FS (P < 0·0001) but not from FPP. In the efficacy trials, body Fe at baseline was a negative predictor of the change in body Fe for both FPP and FS, but the effect was significantly greater with FS (P < 0·001). Because Fe deficiency up-regulates Fe absorption from FS but not from FPP, food fortification with FS may have relatively greater impact in Fe-deficient children. Thus, more soluble Fe compounds not only demonstrate better overall absorption and can be used at lower fortification levels, but they also have the added advantage that, because their absorption is up-regulated in Fe deficiency, they innately ‘target’ Fe-deficient individuals in a population.

Key words: Iron deficiency: Absorption: Fortification: Efficacy: Children

Fe fortification of foods can be an effective strategy to control Fe deficiency(1). The relative bioavailability (RBV) of an Fe compound – its estimated percentage absorption relative to the absorption of ferrous sulphate (FS) – is used to rank Fe fortification compounds and to set food fortification levels(2,3). Ferric pyrophosphate (FPP) is generally less than half as well absorbed as FS(2,3). On this basis, the WHO recommends FS as a first-choice Fe fortificant and recommends that if FPP is used, the fortification level should be doubled(3). The absorption of dietary Fe is dependent on Fe status; the fractional absorption of an oral Fe dose is greater in Fe-deficient individuals than in Fe-sufficient individuals(4). This is a primary homeostatic mechanism controlling body Fe stores in humans and appears to be regulated by circulating hepcidin concentrations(5). It has been traditionally assumed that up-regulation occurs for all Fe compounds equally. However, a recent small study has suggested that the absorption of FS in women with poor Fe status was up-regulated to a greater degree than FPP(6). It was unclear whether this effect was due to the special form of FPP – small particles coated with emulsifiers – used in the study; the findings need confirmation in studies with commercial FPP. But if true, the RBV of an Fe compound may depend on the Fe status of the individual/population. This would limit the use of RBV to rank Fe fortification compounds and to adjust fortification levels. It would also argue strongly for the use of soluble compounds in fortified foods in populations with high rates of Fe deficiency.

Therefore, the aim of the present study was to (1) use stable Fe isotopes to compare the up-regulation of Fe absorption at low Fe status from FS and FPP, (2) determine whether the RBV of FPP varies with Fe status and (3)

Abbreviations: DMT1, divalent metal transport protein 1; FPP, ferric pyrophosphate; FS, ferrous sulphate; RBV, relative bioavailability; SF, serum ferritin; sTfR, serum transferrin receptor.

* Corresponding author: M. B. Zimmermann, email michael.zimmermann@ilw.agrl.ethz.ch
compare the relative efficacy of FPP and FS as fortificants to increase body Fe stores in Fe-deficient children v. Fe-sufficient children.

Materials and methods

Study 1: stable isotope studies

Subjects. A total of forty-nine apparently healthy young women were enrolled: (1) twenty-five women with low Fe status as defined by a plasma ferritin concentration < 25 μg/l with or without anaemia and (2) twenty-four women with Fe sufficiency as defined by plasma ferritin > 40 μg/l and a normal Hb concentration (≥ 120 g/l). Inclusion criteria for both groups were as follows: age 18–40 years; no chronic medical illnesses or medications; body weight ≤ 65 kg; non-pregnant and not planning pregnancy; no blood donation within the previous 4 months; a C-reactive protein concentration < 10 mg/l with or without anaemia and (2) twenty-four women were enrolled: (1) twenty-five women with low Fe status, (2) twenty-five women with Fe sufficiency, and (3) the subjects were 6- to 15-year-old children from the same neighbouring primary schools. The studies were done approximately 2 years apart(11,12). The studies included both Fe-deficient and Fe-sufficient children because all children in the schools were invited to participate in the studies. The children were randomised at the household level into two groups. One group was given iodised salt in northern Morocco, one using FPP and another using FS. The methods and results have been described in detail previously(11,12). The studies were conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the review committee at ETH Zürich. Written informed consent was obtained from all subjects.

Test meal. The test meal was boiled white rice (50 g dry weight) and 25 g (fresh weight) vegetable sauce. The sauce (44% Chinese cabbage, 22% carrots, 22% zucchini and 13% onions) was produced by boiling the vegetables until tender, stir-frying in vegetable oil and then pureeing. All ingredients were purchased in bulk and used for the entire study. The food portions were kept frozen until use, and each portion was microwaved on the day of feeding.

Isotopic analyses. 57Fe-labelled FS was prepared from isotopically enriched 58Fe (Chempas, Boulogne, France) by dilution in 0.1 M-H2SO4. 57Fe-labelled FPP was produced by Paul Lohmann GmbH (Emmerthal, Germany). The isotopic composition of the stable isotope labels was measured by negative thermal ionisation MS(7,8). Enrichment of the isotopic labels was 97.82% for 57Fe and 92.86% for 58Fe. Each isotopically enriched blood sample was analysed in duplicate for its Fe isotopic composition by negative thermal ionisation MS using a magnetic sector field mass spectrometer (MAT 262) equipped with a multi-collector system for simultaneous ion beam detection(7,8). Data were normalised for the natural 56Fe:54Fe isotope ratio(9) to correct for mass-dependent fractionation effects in the ion source. Based on the shift of the Fe isotopic ratios in the blood samples and the amount of Fe circulating in the body, the amounts of 57Fe and 58Fe isotopic label present in the blood 14 d after the test meals were calculated by isotope dilution(10). Circulating Fe was calculated based on the blood, height and weight according to Brown et al.(10). For the calculation of fractional absorption, 80% incorporation of the absorbed Fe into erythrocytes was assumed.

Study 2: efficacy studies

Subjects and study design. We did a secondary analysis of two previous efficacy studies of the Fe fortification of iodised salt in northern Morocco, one using FS and another using FPP. The methods and results have been described in detail previously(11,12). In the FS study, Fe was added at a level of 1 mg/g salt using microencapsulated FS (Cap-Shure FS-165E-50; Balchem, Slate Hill, NY, USA)(11). In the FPP study, Fe was added as micronised FPP (article no. 3043448; Dr Paul Lohmann) at a fortification level of 2 mg Fe/g salt(12). The fortification level was set higher because the RBV of FPP is estimated to be approximately 50% of FS(3).

The design of the two studies was similar. For both studies (1) the salt came from the same local source and was iodised with potassium iodide at 25 μg/g salt, (2) 2 kg of salt was distributed to the participating households monthly for 10 months and (3) the subjects were 6- to 15-year-old children from the same neighbouring primary schools. The studies were done approximately 2 years apart(11,12). The studies were conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the review committee at ETH Zürich and the Ministry of Health in Rabat. Oral informed consent was obtained from all parents of the children. The studies included both Fe-deficient and Fe-sufficient children because all children in the schools were invited to participate in the studies. The children were randomised at the household level into two groups. One group was given iodised salt as a control, while the second group was given the dual-fortified salt with Fe and iodine; the results from the children who received the dual-fortified salt are reported here. At baseline, weight and height were measured, and whole blood was collected by venepuncture.
for the determination of Hb, serum ferritin (SF) and serum transferrin receptor (sTfR). In both studies, these measures were repeated 10 months later\(^{(11,12)}\).

**Laboratory analysis**

**Study 1.** Hb was measured in whole blood on the day of collection using an automated coulter counter (AcT8 Coulter; Beckman Coulter, Krefeld, Germany) with three-level control materials provided by the manufacturer. The plasma was separated and frozen until analysis. Plasma ferritin was measured on an IMMULITE\(^\text{\textregistered}\) automatic system (DPC Bühlmann GmbH, Aschwil, Germany); the normal range was 15–300 \(\mu\)g/l. High-sensitivity C-reactive protein was measured by using IMMULITE; the normal range was < 100 mg/l.

**Study 2.** Hb was measured as above using a Coulter counter. SF and sTfR were measured using an ELISA (Ramco, Houston, TX, USA). Normal reference values are as follows: SF, 12–300 \(\mu\)g/l; sTfR, 2·9–8·5 mg/l. Fe deficiency was defined as either SF < 12 \(\mu\)g/l or sTfR > 8·5 mg/l\(^{(13)}\). Anaemia was defined as Hb < 120 g/l in children aged ≥12 years, and Hb < 115 g/l in children aged 5–11 years\(^{(13)}\). Body Fe was estimated by the method of Cook et al.\(^{(14)}\) using the following formula:

\[
\text{Body Fe (mg/kg)} = -(\log(\text{sTfR/SD}) - 2·8229)/0·1207.
\]

The change in body Fe during the efficacy study was obtained by subtracting the baseline body Fe value from the value at 40 weeks.

**Data analysis**

Data were analysed using SPSS 13.0 for Windows (SPSS, Chicago, IL, USA) and Excel (XP 2002; Microsoft, Seattle, WA, USA). Results are presented as means and standard deviations if normally distributed. If not normally distributed, results are presented as medians (ranges) and log-transformed for comparisons. The \(\chi^2\) and unpaired \(t\) tests were used for comparisons between the groups, and trend line slopes and regressions were done to examine relationships among the variables. \(P\) values < 0·05 were considered to be significant.

**Results**

Table 1 shows the characteristics of the subjects in the low Fe status and Fe-sufficient groups. In the low Fe status group, 66% of women were Fe deficient (plasma ferritin < 15 \(\mu\)g/l) and 18% were Fe-deficient anaemic. In the Fe-sufficient group, Hb and plasma ferritin were significantly higher (\(P<0·05\) and \(P<0·0001\)), while Fe bioavailability from the FS-labelled meal was significantly lower (\(P<0·01\)). However, there was no significant difference in Fe bioavailability from FPP between the Fe-sufficient and low Fe status groups (Table 1).
Discussion

FPP is often used to fortify infant cereals and chocolate drink powders\(^{(2)}\). Its main advantage is that it causes no adverse colour and flavour changes. However, it is poorly soluble in both water and dilute acid, including gastric juice, and is variably absorbed. Human studies have reported absorption values of 20–75% relative to FS depending on food processing, particle size of the fortification and crystal structure\(^{(2)}\). The RBV of FPP (8.3–12.8%) in the present study is somewhat lower than that reported in previous studies, but is generally consistent with previous results using FPP in rice-based meals\(^{(6,15)}\). However, the efficacy of FPP has been demonstrated in salt and rice fortification\(^{(12,15–17)}\).

Moretti et al.\(^{(6)}\) used a dispersible form of submicrometre-sized FPP in a cross-over design to measure Fe bioavailability in young women (n 26) from a wheat-milk infant cereal given with and without ascorbic acid (n 10) and from a processed and unprocessed rice meal (n 16). Of the twenty-six subjects, sixteen were Fe deficient. There was a significant negative correlation between SF and the absorption of FPP from the infant cereal with and without ascorbic acid (r = −0.77, P = 0.010; r = −0.64, P = 0.046, respectively), but in the rice meals, there was no significant relationship. Combining all data, Fe status was a highly significant positive predictor of the RBV of FPP (r = 0.64; P < 0.001)\(^{(6)}\). In the present study, in women selected for a broader range of Fe status, including 18% with Fe-deficiency anaemia, Fe status was again not a significant predictor of the RBV of FPP (r = 0.156; P = 0.01). The slope of the trend line for FS was significantly steeper than that of FPP (P < 0.01). As shown in Fig. 1(b), plasma ferritin was a significant positive predictor of the RBV of FPP (r² 0.156; P < 0.01).

Table 2 shows the characteristics of the children in the two efficacy studies. There were no significant differences between the groups except that the group that received the FS-fortified salt had a higher prevalence of Fe-deficiency anaemia (P < 0.05).

Fig. 2 shows the relationship between body Fe at baseline, calculated from the stTRSF ratio, and the change in body Fe during the 10-month studies. Body Fe at baseline was a stronger negative predictor of the change in body Fe during the intervention with FS (r² 0.467; P < 0.0001) than with FPP (r² 0.169; P < 0.01). The slope of the trend line for FS was significantly steeper than that of FPP (P < 0.05).

### Table 2. Baseline characteristics of the Moroccan children in the efficacy studies who received either iodised salt fortified with ferric pyrophosphate (FPP) or ferrous sulphate (FS)

(Mean values, standard deviations, medians, ranges, number of children and percentages)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Salt fortified with FPP (n 75)</th>
<th>Salt fortified with FS (n 183)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>10.8</td>
<td>10.4</td>
</tr>
<tr>
<td>SD</td>
<td>2.3</td>
<td>2.5</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>35</td>
<td>89</td>
</tr>
<tr>
<td>Male</td>
<td>40</td>
<td>94</td>
</tr>
<tr>
<td>Wt (kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>31.2</td>
<td>29.5</td>
</tr>
<tr>
<td>SD</td>
<td>9.9</td>
<td>9.1</td>
</tr>
<tr>
<td>Ht (m)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>1.34</td>
<td>1.33</td>
</tr>
<tr>
<td>SD</td>
<td>0.14</td>
<td>0.17</td>
</tr>
<tr>
<td>Hb (g/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>113</td>
<td>113</td>
</tr>
<tr>
<td>SD</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Serum ferritin (µg/l)</td>
<td>16</td>
<td>20</td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>6–28</td>
<td>1–79</td>
</tr>
<tr>
<td>Serum transferrin receptor (mg/l)</td>
<td>7.6</td>
<td>8.6</td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>3.8–17.8</td>
<td>4.3–17.1</td>
</tr>
<tr>
<td>Body Fe (mg/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>1.58</td>
<td>2.07</td>
</tr>
<tr>
<td>Range</td>
<td>−4.35–7.19</td>
<td>−17.16–6.47</td>
</tr>
<tr>
<td>Prevalence of Fe-deficiency anaemia</td>
<td>Children (n)</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>31</td>
<td>64</td>
</tr>
<tr>
<td>%</td>
<td>23*</td>
<td>35</td>
</tr>
</tbody>
</table>

* Value was significantly different from the FS group (P < 0.05; χ² test).
Iron absorption and efficacy

**Fig. 2.** Relationship between body Fe at baseline, calculated from the serum transferrin receptor:serum ferritin ratio\(^{26}\), and the change in body Fe in Moroccan children during the 10-month efficacy studies of the salt fortified with (a) ferrous sulphate \((n = 183)\); \(y = -0.8465x + 2.6431; r^2 = 0.4673\) or (b) ferric pyrophosphate \((n = 75)\); \(y = -0.4543x + 3.7082; r^2 = 0.1689\).

A predictor of Fe bioavailability from the commercial form of FPP commonly used as a food fortificant, and there was no significant up-regulation of Fe absorption from FPP in Fe deficiency. Because of this, Fe status was a significant direct predictor of the RBV of FPP \(^{(24)}\). In duodenal biopsy specimens in human subjects, Fe deficiency results in a 4- to 12-fold increase in DMT1 expression. \(v\), normal controls\(^{(25–27)}\). In these studies, DMT1 levels show significant inverse correlations with SF. In contrast, the effect of Fe status on duodenal cytochrome \(b\) expression in humans is unclear\(^{(25,26,28)}\). Several studies have reported no significant up-regulation in Fe deficiency\(^{(25,28)}\). Therefore, the stronger up-regulation of Fe absorption from FS compared with FPP in Fe deficiency may be at least partially explained as follows: in Fe-sufficient subjects, low expression of DMT1 becomes an important limiting factor in Fe absorption, reducing differences in absorption due to the varying solubility of the Fe compounds. But duodenal cytochrome \(b\) expression is not down-regulated, allowing available ferric iron to be converted to the ferrous form for absorption. In Fe deficiency, DMT1 is strongly up-regulated\(^{(25,26,28)}\) and there is ample DMT1 on the apical surface, allowing solubility to emerge as the principal limiting factor in Fe absorption. At the same time, duodenal cytochrome \(b\) is not strongly up-regulated\(^{(25,28)}\), further favouring the absorption of ferrous iron over ferric iron.

Our data suggest that Fe absorption from poorly soluble Fe compounds such as FPP (and possibly elemental Fe compounds) is less well up-regulated by Fe deficiency than Fe absorption from soluble Fe compounds such as FS. Our findings should be confirmed in young children, where the superior organoleptic properties of FPP may be an important consideration. However, they argue that FS should continue to be recommended for the fortification of foods in Fe-deficient populations, while the use of FPP may be less desirable. Compared with poorly soluble compounds, more soluble Fe compounds not only demonstrate better overall absorption and can be used at lower fortification levels, but they also may have the added advantage that, because their absorption is up-regulated in Fe deficiency, they intrinsically target Fe-deficient individuals in a population.

**Acknowledgements**

All authors contributed to the study design, data analysis and writing of the manuscript. R. B., I. E. and C. Z. supervised the Fe absorption studies, and M. B. Z. and C. Z. supervised the fieldwork in Morocco. C. Z. was responsible for the stable isotope analysis. M. B. Z. wrote the first draft of the manuscript, and all authors contributed to its editing.
None of the authors declare any conflicts of interest. The present study was supported by the Swiss Federal Institute of Technology (ETH) Zürich and the Swiss Foundation for Nutrition Research, Zürich, Switzerland. We thank the subjects for their participation in the study and J. Tajeri Foman for her assistance with the study.

References